I established Mingowood Pharmacal alongside a team of seasoned veterans in pharmaceutical development, licensing, and business development dedicated to creating novel acidic cannabinoid products that address unmet needs in multiple disease states. Unleashing the potential of our unique Layered Double Hydroxide (LDH) intercalated delivery system, designed to deliver pharmaceutically active cannabinoids (CBDA and THCA), we are poised to deliver new pharmaceutical and consumer product solutions that align with current regulations and industry standards.We've achieved remarkable results, including creating a robust intellectual property portfolio, optimizing synthesis processes for flexibility in delivery options, and securing access to high-quality, yet cost-effective pharmaceutical-grade excipients from both North America and abroad.Our technology ensures long-term stability at room temperature, far surpassing typical degradation rates. We have executed US and International patents, priority dated to October 2020, showcasing our commitment to innovation.What sets us apart?■ Our process guarantees a THC-free product, in compliance with current regulations, and our intellectual property extends beyond CBDA and THCA, encompassing a range of acidic cannabinoids, without creating New Chemical Entities (NCE). ■ Our technology is readily scalable, utilizing commonly employed pharmaceutical equipment and techniques. It allows for multiple formulation techniques and nanoparticle sizing, offering versatility in product development. Additionally, our finished products will boast significantly extended room temperature shelf life, eliminating the need for cold chain supply. Our process utilizes only FDA listed GRAS excipients, ensuring safety and quality in our finished products. If you are interested in exploring potential partnership or joint venture, reach out to connect and let's join forces.

Leveraging a career background advancing healthcare and enhancing patient care, gathered a dedicated team of professionals that developed, commercialized, and licensed the LyoCell™ platform, an innovative lyotropic liquid nanocrystalline phase technologies. One of our most significant achievements was the development of Ryanodex™, a vital medication in treating the pharmacogenetic disorder, Malignant Hyperthermia, as well as other injectable anesthetic medications. These medications drove a significant advancement in the field of anesthesia due to its unique formulation, features and benefits. We also secured Orphan Drug Designation and additional FDA indications, leading to the approval of Ryanodex™ in August 2014. The product is now licensed and currently marketed by Eagle Pharmaceuticals (EGRX).

Shaped direction and growth of this company harnessing the power of the innovative LyoCell™ drug delivery system, beginning with a vision to address unmet medical needs in anesthesia, pain management, ophthalmology, and oncology. ■ Established and led pre-clinical and clinical trial programs for novel 505(b)2 products, developing 'super-generic' anesthetic products, including Dantrolene sodium, Propofol, Etomidate, Vecuronium, Bupivacaine, Ropivacaine, and a unique rescue agent for reversal of local anesthetic systemic toxicity (LAST).■ Coordinated FDA Regulatory Team, consisting of in-house experts, licensees, and consultants, for innovative high concentration/low volume dantrolene sodium formulation, Ryanodex™

Recruited by MedStream Anesthesia Solutions as Medical Director, managing an Anesthesia Care Team model in two newly contracted hospitals. Repositioned to assist in cardiovascular care as well as all other duties during COVID crisis. Retained by Medical University of South Carolina in 2021 – duties include: cardiovascular, vascular, thoracic, general, neuro/neuro-spine, pediatric, OB/GYN, orthopedics, ortho-spine, urology, robotics team.

Neuro-anesthesia, interventional neuroradiology, obstetrics, trauma, general, thoracic, orthopedics, urology, operative and post-operative regional blocks. Resident and student peri-operative educational instruction.

Interventional pain management specialist; RFA, spinal cord stimulator trials, neuraxial procedures, sphenopalatine ganglion, and other regional nerve blocks